Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Biogen Idec Hoffmann-La Roche Genentech |
---|---|
Information provided by: | Biogen Idec |
ClinicalTrials.gov Identifier: | NCT00468546 |
The purpose of this study is to determine whether rituximab is safe and effective in the treatment of rheumatoid arthritis in patients who no longer respond to anti-TNF therapies.
Condition | Intervention | Phase |
---|---|---|
Arthritis, Rheumatoid |
Biological: Rituximab Other: Placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNFα Therapies |
Enrollment: | 520 |
Study Start Date: | July 2003 |
Primary Completion Date: | January 2005 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Biological: Rituximab
rituximab 1000 mg i.v. on Days 1 and 15
|
2: Placebo Comparator |
Other: Placebo
Placebo i.v. on Days 1 and 15
|
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Excluded Previous/Concomitant Medications:
Exclusions for General Safety:
Laboratory Exclusion Criteria (at Screening):
Responsible Party: | Biogen Idec ( Biogen Idec MD ) |
Study ID Numbers: | 102-20, Protocol WA17042D |
Study First Received: | April 30, 2007 |
Last Updated: | February 5, 2008 |
ClinicalTrials.gov Identifier: | NCT00468546 |
Health Authority: | United States: Food and Drug Administration |
Folic Acid Autoimmune Diseases Musculoskeletal Diseases Rituximab Joint Diseases |
Arthritis Connective Tissue Diseases Arthritis, Rheumatoid Methotrexate Rheumatic Diseases |
Antimetabolites Antimetabolites, Antineoplastic Immunologic Factors Immune System Diseases Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Physiological Effects of Drugs Enzyme Inhibitors Reproductive Control Agents |
Folic Acid Antagonists Abortifacient Agents, Nonsteroidal Immunosuppressive Agents Pharmacologic Actions Therapeutic Uses Abortifacient Agents Antirheumatic Agents Dermatologic Agents Nucleic Acid Synthesis Inhibitors |